Enterprise Value

-32.64M

Cash

44.74M

Avg Qtr Burn

-6.138M

Short % of Float

0.64%

Insider Ownership

29.53%

Institutional Own.

55.71%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NX-13 Details
Ulcerative colitis

Phase 2

Data readout

Omilancor Details
Eosinophilic Esophagitis

Failed

Discontinued

Failed

Discontinued

LABP-104 Details
Rheumatoid arthritis

Failed

Discontinued

Failed

Discontinued

LABP-104 Details
Systemic lupus erythematosus

Failed

Discontinued

NX-13 Details
Crohns disease

Failed

Discontinued

Omilancor (BT-11) Details
Ulcerative colitis

Failed

Discontinued